Skip to content

Author

Ahmed Shaheen

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Sep 2026

One target, two evidence streams: Rituximab versus ocrelizumab in relapsing multiple sclerosis: A design-stratified systematic review, meta-analysis, and concordance assessment.

PURPOSE Rituximab is widely used off-label as a lower-cost alternative to ocrelizumab for relapsing multiple sclerosis (MS), but comparative effectiveness and safety remain uncertain. We assessed direct head-to-head evidence and concordance between randomized and real-world findings. METHODS PubMed/MEDLINE, Cochrane...

Yehia Nabil, Ahmed Shaheen, Anas Mansour et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.